Literature DB >> 23434041

Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study.

Theddeus Iheanacho1, Mohammed Issa, Carla Marienfeld, Robert Rosenheck.   

Abstract

BACKGROUND: This study aimed to determine the proportion of patients with alcohol use disorders who were prescribed naltrexone in Veterans Administration (VA) Healthcare system for fiscal year (FY) 2010 and socio-demographic and clinical factors associated with its use.
METHODS: VA national administrative data were used to identify all veterans who had an alcohol use disorder diagnosis (ICD-9-CM codes 303.9x or305.0x) in fiscal year (FY 2010) and were not prescribed any opioids (n=224,319). Patients in this group who filled a naltrexone prescription during this period were identified. Bivariate analysis was used to evaluate differences between veterans who received naltrexone prescription and those who did not on baseline characteristics and diagnoses. Multivariate logistic regression analysis identified measures that were independently related to receipt of naltrexone.
RESULTS: 6172 (2.75%) of the 224,319 patients with a diagnosis of alcohol use disorder who did not receive a prescription for opioid medications received naltrexone prescription. Bivariate analyses showed that patients taking naltrexone were 69 times more likely to have a co-morbid axis I diagnosis. Multivariate logistic regression analysis showed that a history of any substance abuse outpatient visit, any psychiatric outpatient visit or any mental health inpatient hospitalization, were significantly related to filling a prescription for naltrexone.
CONCLUSIONS: The rate of use of naltrexone by clinicians and patients remains low and having a co-morbid axis I diagnosis and receiving specialty mental health care were strong predictors of receiving a naltrexone prescription. Understanding the reasons for these findings may further naltrexone's clinical usefulness.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alcohol; Co-morbidity; Naltrexone; Prescription; Sociodemographic factors; VA; Veteran's Administration

Mesh:

Substances:

Year:  2013        PMID: 23434041     DOI: 10.1016/j.drugalcdep.2013.01.016

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

1.  Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders.

Authors:  Paul J Joudrey; Benjamin J Oldfield; Kimberly A Yonkers; Patrick G O'Connor; Gretchen Berland; E Jennifer Edelman
Journal:  Drug Alcohol Depend       Date:  2020-06-02       Impact factor: 4.492

Review 2.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

Review 3.  Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.

Authors:  Martyna Sawicka; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2017-05-24

4.  First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.

Authors:  Sheryl Spithoff; Suzanne Turner; Tara Gomes; Diana Martins; Samantha Singh
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

5.  The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients.

Authors:  E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Amy C Justice; Kendall J Bryant; David A Fiellin
Journal:  Contemp Clin Trials       Date:  2016-11-20       Impact factor: 2.226

6.  Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population.

Authors:  Haiden A Huskamp; Sharon Reif; Shelly F Greenfield; Sharon-Lise T Normand; Alisa B Busch
Journal:  J Gen Intern Med       Date:  2020-08-04       Impact factor: 5.128

7.  Access to Addiction Pharmacotherapy in Private Health Plans.

Authors:  Sharon Reif; Constance M Horgan; Dominic Hodgkin; Ann-Marie Matteucci; Timothy B Creedon; Maureen T Stewart
Journal:  J Subst Abuse Treat       Date:  2016-03-14

8.  Primary care engagement is associated with increased pharmacotherapy prescribing for alcohol use disorder (AUD).

Authors:  Paul J Joudrey; Mat Kladney; Chinazo O Cunningham; Marcus A Bachhuber
Journal:  Addict Sci Clin Pract       Date:  2019-05-01

9.  Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics.

Authors:  E Jennifer Edelman; Nathan B Hansen; Christopher J Cutter; Cheryl Danton; Lynn E Fiellin; Patrick G O'Connor; Emily C Williams; Stephen A Maisto; Kendall J Bryant; David A Fiellin
Journal:  Addict Sci Clin Pract       Date:  2016-01-13

10.  Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder.

Authors:  Jarrod Ehrie; Emily E Hartwell; Paige E Morris; Tami L Mark; Henry R Kranzler
Journal:  Front Psychiatry       Date:  2020-02-14       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.